Unknown

Dataset Information

0

The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy.


ABSTRACT: 5-Fluorouracil (5-FU)-based chemotherapy is the first-line treatment for colorectal cancer (CRC) but is hampered by chemoresistance. Despite its impact on patient survival, the mechanism underlying chemoresistance against 5-FU remains poorly understood. Here, we identified serine hydroxymethyltransferase-2 (SHMT2) as a critical regulator of 5-FU chemoresistance in CRC. SHMT2 inhibits autophagy by binding cytosolic p53 instead of metabolism. SHMT2 prevents cytosolic p53 degradation by inhibiting the binding of p53 and HDM2. Under 5-FU treatment, SHMT2 depletion promotes autophagy and inhibits apoptosis. Autophagy inhibitors decrease low SHMT2-induced 5-FU resistance in vitro and in vivo. Finally, the lethality of 5-FU treatment to CRC cells was enhanced by treatment with the autophagy inhibitor chloroquine in patient-derived and CRC cell xenograft models. Taken together, our findings indicate that autophagy induced by low SHMT2 levels mediates 5-FU resistance in CRC. These results reveal the SHMT2-p53 interaction as a novel therapeutic target and provide a potential opportunity to reduce chemoresistance.

SUBMITTER: Chen J 

PROVIDER: S-EPMC8195740 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy.

Chen Jian J   Na Risi R   Xiao Chao C   Wang Xiao X   Wang Yupeng Y   Yan Dongwang D   Song Guohe G   Liu Xueni X   Chen Jiayi J   Lu Huijun H   Chen Chunyan C   Tang Huamei H   Zhuang Guohong G   Fan Guangjian G   Peng Zhihai Z  

Oncogene 20210514 23


5-Fluorouracil (5-FU)-based chemotherapy is the first-line treatment for colorectal cancer (CRC) but is hampered by chemoresistance. Despite its impact on patient survival, the mechanism underlying chemoresistance against 5-FU remains poorly understood. Here, we identified serine hydroxymethyltransferase-2 (SHMT2) as a critical regulator of 5-FU chemoresistance in CRC. SHMT2 inhibits autophagy by binding cytosolic p53 instead of metabolism. SHMT2 prevents cytosolic p53 degradation by inhibiting  ...[more]

Similar Datasets

| S-EPMC6962897 | biostudies-literature
| S-EPMC9937894 | biostudies-literature
| S-EPMC6070274 | biostudies-literature
| S-EPMC5839414 | biostudies-literature
| S-EPMC6795411 | biostudies-literature
| S-EPMC5767127 | biostudies-literature
| S-EPMC10313691 | biostudies-literature
2025-05-07 | PXD053068 | Pride
| S-EPMC7867943 | biostudies-literature
| S-EPMC6327560 | biostudies-literature